Document is current
Any future updates will be listed below
-
Authors
Vigers, Timothy https://orcid.org/0000-0001-7087-8570
Vinovskis, Carissa
Li, Lu-Ping
Prasad, Pottumarthi
Heerspink, Hiddo
D’Alessandro, Angelo
Reisz, Julie A.
Piani, Federica
Cherney, David Z.
van Raalte, Daniel H.
Nadeau, Kristen J.
Pavkov, Meda E.
Nelson, Robert G.
Pyle, Laura
Bjornstad, Petter
-
Funding
Funding for this research was provided by:
NIDDK Diabetic Complications Consortium (DK076169)
- License Information
-
More Information
Article History
Received: 23 November 2021
Revised: 25 February 2022
Accepted: 7 March 2022
First Online: 4 May 2022
Declarations
:
: The research protocols of CASPER and Renal-HEIR were approved by COMIRB, and all participants gave written informed consent.
: TV: none. CV: none. LL: none. PP: none. HH: none. AD: none. JAR: none. FP: none. DZC: none. DHvR: none. KJN: none. MEP: none. RGN: none. LP: none. PB: has acted as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli-Lilly, Sanofi, Novo Nordisk, and Horizon Pharma. PB serves on the advisory boards of AstraZeneca, Boehringer Ingelheim, and XORTX.
: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
